Design of a novel MDM2 binding peptide based on the p53 family

Cell Cycle

Volumn 8, Issue 17, 2009, Pages 2828-2836

  Arumugam, Madhumalar ^a   Jun, Lee Hui ^a   Brown, Christopher J ^b   Lane, David ^b   Verma, Chandra ^a  

^a BIOINFORMATICS INSTITUTE   (Singapore)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

MDM2; MDMX; Molecular simulations; p53 family; Peptides

Indexed keywords

PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; PROTEIN P63; PROTEIN P73;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; DENATURATION; HUMAN; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION;

EID: 69749117590     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.17.9516     Document Type: Article

References (50)

1. Momand J, Wu HH, Dasgupta G. Mdm2 - Master regulator of the p53 tumor suppressor protein. Gene 2000; 242:15-29. (Pubitemid 30064488)
2. Harris CC. p53 tumor suppressor gene: From the basic research laboratory to the clinic - an abridged historical perspective. Carcinogenesis 1996; 17:1187-1198
3. el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol 1998; 8:345-357
4. Arrowsmith CH, Morin P. New insights into p53 function from structural studies. Oncogene 1996; 12:1379-1385 (Pubitemid 26132031)
5. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387:296-299 (Pubitemid 27220766)
6. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358:80-83
7. Marchetti A, Buttitta F, Pellegrini S, Merlo G, Chella A, Angeletti CA, et al. Mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. Diagn Mol Pathol 1995; 4:93-97
8. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the Mdm2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53:2736-2739 (Pubitemid 23180507)
9. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M. The human Mdm-2 oncogene is overexpressed in leukemias. Blood 1993; 82:2617-2623
10. Wade M, Wahl GM. Targeting Mdm2 and Mdmx in cancer therapy: Better living through medicinal chemistry? Mol Cancer Res 2009; 7:1-11.
11. Vassilev LT. Mdm2 inhibitors for cancer therapy. Trends Mol Med 2007; 13:23-31.
12. Lin J, Chen J, Elenbaas B, Levine AJ. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to Mdm-2 and the adenovirus 5 E1b 55-Kd protein. Genes Dev 1994; 8:1235-1246 (Pubitemid 24163450)
13. Uesugi M, Verdine GL. The alpha-helical Fxxphiphi motif in p53: Taf interaction and discrimination by Mdm2. Proc Natl Acad Sci USA 1999; 96:14801-14806 (Pubitemid 30019720)
14. Vassilev LT. Small-molecule antagonists of p53-Mdm2 binding: Research tools and potential therapeutics. Cell Cycle 2004; 3:419-421
15. Shangary S, Wang S. Targeting the Mdm2-p53 interaction for cancer therapy. Clin Cancer Res 2008; 14:5318-5324
16. Robinson JA. Beta-hairpin peptidomimetics: Design, structures and biological activities. Acc Chem Res 2008; 41:1278-1288
17. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing and dominant-negative activities. Mol Cell 1998; 2:305-316
18. Jost CA, Marin MC, Kaelin WG Jr. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 1997; 389:191-194
19. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90:809-819 (Pubitemid 27357971)
20. Vousden KH, Lu X. Live or let die: The cell's response to p53. Nat Rev Cancer 2002; 2:594-604. (Pubitemid 37328926)
21. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398:714-718 (Pubitemid 29197650)
22. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398:708-713 (Pubitemid 29197649)
23. Barbieri CE, Pietenpol JA. p63 and epithelial biology. Exp Cell Res 2006; 312:695-706.
24. Koster MI, Roop DR. p63 and epithelial appendage development. Differentiation 2004; 72:364-370
25. van Bokhoven H, McKeon F. Mutations in the p53 homolog p63: Allele-specific developmental syndromes in humans. Trends Mol Med 2002; 8:133-139 (Pubitemid 34532639)
26. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G. The p53/p63/p73 family of transcription factors: Overlapping and distinct functions. J Cell Sci 2000; 113:1661-1670 (Pubitemid 30333115)
27. Ying H, Chang DL, Zheng H, McKeon F, Xiao ZX. DNA-binding and transactivation activities are essential for Tap63 protein degradation. Mol Cell Biol 2005; 25:6154-6164 (Pubitemid 40946565)
28. Balint E, Bates S, Vousden KH. Mdm2 binds p73alpha without targeting degradation. Oncogene 1999; 18:3923-3929 (Pubitemid 29361329)
29. Dobbelstein M, Wienzek S, Konig C, Roth J. Inactivation of the p53-homologue p73 by the Mdm2-oncoprotein. Oncogene 1999; 18:2101-2106
30. Lohrum MA, Vousden KH. Regulation and activation of p53 and its family members. Cell Death Differ 1999; 6:1162-1168 (Pubitemid 30047892)
31. Ongkeko WM, Wang XQ, Siu WY, Lau AW, Yamashita K, Harris AL, et al. Mdm2 and Mdmx bind and stabilize the p53-related protein p73. Curr Biol 1999; 9:829-832 (Pubitemid 29375186)
32. Zeng X, Chen L, Jost CA, Maya R, Keller D, Wang X, et al. Mdm2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 1999; 19:3257-3266 (Pubitemid 29193787)
33. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, et al. Structure of the Mdm2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996; 274:948-953 (Pubitemid 26398409)
34. Bottger V, Bottger A, Garcia-Echeverria C, Ramos YF, van der Eb AJ, Jochemsen AG, et al. Comparative study of the p53-Mdm2 and p53-Mdmx interfaces. Oncogene 1999; 18:189-199 (Pubitemid 29060593)
35. Lee HJ, Srinivasan D, Coomber D, Lane DP, Verma CS. Modulation of the p53-Mdm2 interaction by phosphorylation of Thr18: A computational study. Cell Cycle 2007; 6:2604-2611 (Pubitemid 350224041)
36. Lees-Miller SP, Sakaguchi K, Ullrich SJ, Appella E, Anderson CW. Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol Cell Biol 1992; 12:5041-5049
37. Lee H, Mok KH, Muhandiram R, Park KH, Suk JE, Kim DH, et al. Local structural elements in the mostly unstructured transcriptional activation domain of human p53. J Biol Chem 2000; 275:29426-29432 (Pubitemid 32043817)
38. Zhong H, Carlson HA. Computational studies and peptidomimetic design for the human p53-Mdm2 complex. Proteins 2005; 58:222-234 (Pubitemid 39665633)
39. Schon O, Friedler A, Bycroft M, Freund SM, Fersht AR. Molecular mechanism of the interaction between Mdm2 and p53. J Mol Biol 2002; 323:491-501. (Pubitemid 35283675)
40. Dastidar SG, Lane DP, Verma CS. Multiple peptide conformations give rise to similar binding affinities: Molecular simulations of p53-Mdm2. J Am Chem Soc 2008; 130:13514-13515
41. Hu B, Gilkes DM, Chen J. Efficient p53 activation and apoptosis by simultaneous disruption of binding to Mdm2 and Mdmx. Cancer Res 2007; 67:8810-8817 (Pubitemid 47437457)
42. Pazgier M, Liu M, Zou G, Yuan W, Li C, Li J, et al. Structural basis for high-affinity peptide inhibition of p53 interactions with Mdm2 and Mdmx. Proc Natl Acad Sci USA 2009; 106:4665-4670
43. Kallen J, Goepfert A, Blechschmidt A, Izaac A, Geiser M, Tavares G, et al. Crystal structures of human Mdmx (Hdmx) in complex with p53 peptide analogues reveal surprising conformational changes. J Biol Chem 2009; 284:8812-8821
44. Macchiarulo A, Pellicciari R. Mdm2/Mdmx inhibitor peptide: Wo2008106507. Expert Opin Ther Pat 2009; 19:721-726
45. Popowicz GM, Czarna A, Holak TA. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle 2008; 7:2441-2443
46. Kutchukian PS, Yang JS, Verdine GL, Shakhnovich EI. All-atom model for stabilization of alpha-helical structure in peptides by hydrocarbon staples. J Am Chem Soc 2009; 131:4622-4627
47. Bernal F, Tyler AF, Korsmeyer SJ, Walensky LD, Verdine GL. Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J Am Chem Soc 2007; 129:2456-2457 (Pubitemid 46364050)
48. Ferreon JC, Lee CW, Arai M, Martinez-Yamout MA, Dyson HJ, Wright PE. Cooperative regulation of p53 by modulation of ternary complex formation with Cbp/P300 and Hdm2. Proc Natl Acad Sci USA 2009; 106:6591-6596
49. Kumar S, Ma B, Tsai CJ, Sinha N, Nussinov R. Folding and binding cascades: Dynamic landscapes and population shifts. Protein Sci 2000; 9:10-19 (Pubitemid 30070934)
50. Hegler JA, Weinkam P, Wolynes PG. The spectrum of biomolecular states and motions. Hfsp J 2008; 2:307-313